NASDAQ:BEAT - BioTelemetry Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $57.80
  • Forecasted Upside: -19.68 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$71.96
+0.30 (1.20%)
Get New BioTelemetry Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BEAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAT

Average Price Target: $57.80
▼ -19.68% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for BioTelemetry in the last 3 months. The average price target is $57.80, with a high forecast of $72.00 and a low forecast of $43.00. The average price target represents a -19.68% upside from the last price of $71.96.

Hold

The current consensus among 7 polled investment analysts is to hold stock in BioTelemetry. This rating has held steady since October 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2020TruistDowngradeBuy ➝ Hold$58.00 ➝ $72.00N/A
12/21/2020Colliers SecuritiesDowngradeBuy ➝ NeutralLow
12/18/2020SidotiDowngradeBuy ➝ NeutralLow
12/18/2020Needham & Company LLCDowngradeBuy ➝ Hold$52.00High
12/3/2020BenchmarkBoost Price TargetPositive ➝ Buy$52.00 ➝ $64.00Medium
9/11/2020Needham & Company LLCInitiated CoverageBuy$52.00High
9/1/2020Robert W. BairdInitiated CoverageNeutral$43.00Medium
7/8/2020SunTrust BanksReiterated RatingBuy$58.00Medium
3/19/2020BenchmarkLower Price TargetBuy$82.00 ➝ $55.00High
2/27/2020SidotiLower Price TargetBuy$81.00 ➝ $75.00High
1/7/2020SunTrust BanksInitiated CoverageBuy$58.00High
11/6/2019Lake Street CapitalReiterated RatingBuy$90.00 ➝ $80.00High
8/2/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
7/31/2019Lake Street CapitalSet Price TargetBuy$90.00High
7/31/2019SidotiLower Price TargetBuy$95.00 ➝ $87.00Medium
7/31/2019Raymond JamesLower Price TargetOutperform$62.00 ➝ $54.00High
4/26/2019Dougherty & CoReiterated RatingBuy ➝ Buy$81.00 ➝ $75.00Low
4/2/2019BenchmarkSet Price TargetBuy$82.00Low
2/22/2019Lake Street CapitalSet Price TargetBuy$90.00High
2/5/2019SidotiSet Price TargetBuy$95.00Medium
10/31/2018Raymond JamesLower Price TargetOutperform ➝ Outperform$66.00 ➝ $64.00High
9/14/2018Raymond JamesBoost Price TargetOutperform$57.00 ➝ $66.00Medium
8/31/2018SunTrust BanksBoost Price TargetBuy$67.00High
7/26/2018Lake Street CapitalBoost Price TargetBuy$50.00 ➝ $90.00High
6/20/2018BenchmarkBoost Price TargetBuy$46.00 ➝ $54.00Medium
4/26/2018BenchmarkReiterated RatingBuy ➝ Buy$44.00 ➝ $46.00High
2/23/2018Dougherty & CoReiterated RatingBuy ➝ Buy$40.00 ➝ $41.00Low
11/8/2017Dougherty & CoReiterated RatingBuy$40.00N/A
10/26/2017Raymond JamesInitiated CoverageOutperform$37.00N/A
10/23/2017SunTrust BanksInitiated CoverageBuy$41.00N/A
9/15/2017Off Wall StreetInitiated CoverageSellMedium
8/10/2017SidotiReiterated RatingBuy$42.00 ➝ $49.00Low
8/9/2017Dougherty & CoBoost Price TargetBuy$37.00 ➝ $40.00High
7/19/2017BenchmarkBoost Price TargetBuy ➝ Buy$38.00 ➝ $44.00Low
7/14/2017Lake Street CapitalReiterated RatingBuy$35.00 ➝ $50.00High
6/29/2017BenchmarkInitiated CoverageBuy$38.00Medium
4/11/2017Dougherty & CoBoost Price TargetBuy ➝ Buy$30.00 ➝ $37.00Low
12/13/2016GabelliReiterated RatingBuyN/A
12/2/2016Dougherty & CoInitiated CoverageBuy$26.00N/A
10/5/2016Lake Street CapitalReiterated RatingBuy$24.00N/A
9/13/2016SidotiInitiated CoverageBuy$27.00N/A
8/3/2016BenchmarkBoost Price TargetBuy$20.00 ➝ $25.00N/A
(Data available from 6/21/2016 forward)
BioTelemetry logo
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $71.96
Low: $71.96
High: $71.96

50 Day Range

MA: $71.92
Low: $71.46
High: $72.27

52 Week Range

Now: $71.96
Low: $27.35
High: $73.10

Volume

N/A

Average Volume

978,536 shs

Market Capitalization

$2.47 billion

P/E Ratio

153.11

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of BioTelemetry?

The following Wall Street sell-side analysts have issued research reports on BioTelemetry in the last twelve months: Benchmark Co., Colliers Securities, Needham & Company LLC, Robert W. Baird, Sidoti, SunTrust Banks, Inc., Truist, and Zacks Investment Research.
View the latest analyst ratings for BEAT.

What is the current price target for BioTelemetry?

5 Wall Street analysts have set twelve-month price targets for BioTelemetry in the last year. Their average twelve-month price target is $57.80, suggesting a possible downside of 19.7%. Truist has the highest price target set, predicting BEAT will reach $72.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $43.00 for BioTelemetry in the next year.
View the latest price targets for BEAT.

What is the current consensus analyst rating for BioTelemetry?

BioTelemetry currently has 5 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BEAT, but not buy more shares or sell existing shares.
View the latest ratings for BEAT.

What other companies compete with BioTelemetry?

Other companies that are similar to BioTelemetry include Acadia Healthcare, Hanger, Aesthetic Medical International Holdings Group, IMAC, BioCorRx, Ceres Ventures and AAC.

How do I contact BioTelemetry's investor relations team?

BioTelemetry's physical mailing address is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. The medical research company's listed phone number is 610-729-7000 and its investor relations email address is [email protected] The official website for BioTelemetry is www.gobio.com.